Hematologic Oncology Update Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
May 3, 2025
Dr. Jennifer R Brown, a leader in CLL research at Dana-Farber, and Prof. Paolo Ghia from Milan, dive into the latest breakthroughs in chronic lymphocytic leukemia. They explore the role of new therapies like BTK inhibitors, comparing their effectiveness with traditional treatments. The conversation highlights the significance of monitoring minimal residual disease and discusses recent findings on treatment risks like hypertension. They also touch on innovative strategies emerged during the COVID-19 pandemic, paving the way for future advancements in CLL care.
AI Snips
Chapters
Transcript
Episode notes
Manage BTK and Atrial Fibrillation
- Avoid concomitant warfarin use with BTK inhibitors; prefer DOACs or Lovenox for anticoagulation.
- Manage atrial fibrillation by continuing BTK inhibitors when stable; hold therapy only in acute, uncontrolled cases.
Monitor Hypertension on BTK Therapy
- Monitor blood pressure regularly during BTK therapy, especially as hypertension tends to develop later.
- Hypertension should not drive BTK choice but requires clinical observation and management.
Venetoclax Combo Shows Durable Control
- Venetoclax plus obinutuzumab shows prolonged PFS but no plateau or cure at six years, especially in high-risk patients.
- Patients with undetectable MRD fare better but still face steady recurrence requiring retreatment.